ClinicalTrials.gg

Program

clazakizumab

Also written as “BMS-945429”, “ALD518” and “Clazakizumab”.

Its studies are mostly in Arthritis, Rheumatoid · Atherosclerosis · Crohn Disease · Arthritis, Psoriatic · Stomatitis, led by 2 companies.

Furthest: phase 3, since Nov 6, 201810 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL90 open or runningphase 3since Nov 6, 2018Mar 20, 2009none ahead
Eli Lilly11 open or runningphase 2since Aug 21, 2026Aug 21, 2026May 2027phase 2 · NCT07783802
  • Named in Eli Lilly’s own pipeline as Clazakizumab, phase 2, as of Oct 29, 2026 (source).

Also a collaborator on its studies: icon-clinical-research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 20, 2009First studies: 2 phase 2 studiesNew to CSLCSL · NCT00867516, NCT00866970
  2. Jun 13, 2011Phase 2 study in Arthritis, RheumatoidCSL · NCT01373151 · 418 enrolled · United States, Argentina, Belgium and more
  3. Jul 25, 2011Phase 2 study in StomatitisCSL · NCT01403064 · 76 enrolled · United States, Australia, Austria and more
  4. Nov 14, 2011Phase 2 study in Arthritis, PsoriaticCSL · NCT01490450 · 165 enrolled · United States, Argentina, Australia and more
  5. Feb 6, 2012Phase 2 study in Acute GvHDCSL · NCT01530256 · 3 enrolled · United States
  6. Mar 1, 2012Phase 2 study in Crohn DiseaseCSL · NCT01545050 · 72 enrolled · United States, Austria, Canada and more
  7. Dec 6, 2013Phase 2 study in Arthritis, RheumatoidCSL · NCT02015520 · 143 enrolled · United States, Argentina, Canada and more
  8. Nov 6, 2018Phase 3 study in Antibody-mediated RejectionCSL · NCT03744910 · 194 enrolled · United States, Australia, Austria and more
  9. Aug 21, 2026Eli Lilly's first study: phase 2 study in AtherosclerosisNew to Eli LillyEli Lilly · NCT07783802 · 120 planned · United States, Argentina, Japan and more

Ahead

  1. May 2027Primary completion: phase 2 study in AtherosclerosisEli Lilly · NCT07783802

TargetBeta

“A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (Il-6) with potential immunomodulating activity. Upon administration, clazakizumab binds to and blocks the activity of IL-6, which may mitigate the catabolic effects of IL-6.”NCIt, read by Claude
“Interleukin-6 inhibitor”ChEMBL 37, by rule

Other programs on IL6

ProgramCompanyFurthest phaseStudies
olokizumabruleR-Pharmphase 319
ziltivekimabruleNovo Nordiskphase 312
pacibekitugruleNovartisphase 31
isomyosamineruletnf-pharmaceuticals-incphase 21

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07783802Atherosclerosis · United States, Argentina, Japan and more2RecruitingEli LillyMay 2027120
NCT03744910Antibody-mediated Rejection · United States, Australia, Austria and more3TerminatedCSLApr 8, 2024194
NCT02015520Arthritis, Rheumatoid · United States, Argentina, Canada and more2CompletedCSLJun 2013143
NCT01545050Crohn Disease · United States, Austria, Canada and more2TerminatedCSLDec 201372
NCT01530256Acute GvHD · United States2TerminatedCSLMar 20133
NCT01490450Arthritis, Psoriatic · United States, Argentina, Australia and more2CompletedCSLJun 2013165
NCT01403064Stomatitis · United States, Australia, Austria and more2TerminatedCSLApr 201376
NCT01373151Arthritis, Rheumatoid · United States, Argentina, Belgium and more2CompletedCSLSep 2012418
NCT00867516Arthritis, Rheumatoid · Canada, Georgia, India and more2CompletedCSLJun 2009127
NCT00866970Fatigue · Australia, Canada, Georgia and more2CompletedCSLAug 2009124

How it is read

Names in the registry

  • “BMS-945429”, 16 entries
  • “ALD518”, 8 entries
  • “Clazakizumab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.